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Abstract: MicroRNAs (miRNAs) are small non-coding RNAs (18–22 nt) that function as modulators
of gene expression. Since their discovery in 1993 in C. elegans, our knowledge about their biogenesis,
function, and mechanism of action has increased enormously, especially in recent years, with the
development of deep-sequencing technologies. New biogenesis pathways and sources of miRNAs are
changing our concept about these molecules. The study of the miRNA contribution to pathological
states is a field of great interest in research. Different groups have reported the implication of
miRNAs in pathologies such as cancer, diabetes, cardiovascular, and gynecological diseases. It is
also well-known that miRNAs are present in biofluids (plasma, serum, urine, semen, and menstrual
blood) and have been proposed as ideal candidates as disease biomarkers. The goal of this review is
to highlight the current knowledge in the field of miRNAs with a special emphasis to their role in
endometriosis and the newest investigations addressing the use of miRNAs as biomarkers for this
gynecological disease.
Keywords: non-coding RNA; microRNA; biomarker; endometriosis
1. Introduction
Traditionally, in all eukaryotic systems, genes codified proteins, following the central dogma of
molecular biology [1] consisting of DNA being transcribed into mRNA and mRNA translated into
proteins. The first non-coding RNA (ncRNA) characterized was an alanine tRNA found in baker’s
yeast in 1965 [2]. Since then, our understanding of the different and capital roles they play in cells and
organisms development and functions has enormously increased. ncRNAs are also assumed to be
genomic regulators at different levels and, in case of lower level of sequence conservation, are assumed
as evolutionary and biodiversity repositories [3].
Nowadays, it is evident that that RNA is not just a simple messenger between DNA and
proteins but growing evidence supports new roles for these molecules, such as regulation of genome
organization and gene expression. ncRNAs seem to act at many levels playing important roles in
epigenetic processes by controlling differentiation and development and they have been related to
very different pathologies (Table 1). Short and long ncRNAs are key regulators of gene expression,
genome stability, and defense against foreign genetic elements. ncRNAs are encoded in the genome
Int. J. Mol. Sci. 2016, 17, 93; doi:10.3390/ijms17010093 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 93 2 of 16
and never become proteins, demonstrating that the first assumed functions for those molecules have
been a lot less than expected [4].
Table 1. Classes of non-coding RNAs (ncRNA).
Symbol Non-Coding RNAs Functions
tRNA Transfer RNA mRNA translation (structural)
rRNA Ribosomal RNA mRNA translation (structural)
miRNA micro RNAs Post-transcriptional transposon repression
piRNA Piwi-interacting RNA DNA methylation, transposon repression
siRNA Short interfering RNA RNA interference
snoRNA Small nucleolar RNAs RNA modification, rRNA processing
PROMPT’s Promoter upstream transcripts Associated with chromatin changes
tiRNAs Transcripton initation RNAs Epigenetic regulation
lincRNAs Long intergenic ncRNA Epigenetic regulators of transcription
rasiRNA Repeat associated small interfering RNA Involved in the RNA interference(RNAi) pathway
eRNA Enhancer-like ncRNA Transcriptional gene activation
T-UCRs Transcribed ultraconserved regions Regulation of miRNA and mRNA levels
NATs Natural antisense transcripts mRNA stability
PALRs Promoter-associated long RNAs Chromatin changes
tasiRNA Trans-acting siRNA Represses gene expression
lncRNA Long noncoding RNA Regulation of gene transcription
2. Non-Coding RNA Identification: The ENCODE Project
ncRNAs are RNA fragments that are transcribed from DNA but are not translated into
proteins. The main function of ncRNAs is to regulate gene expression at the transcriptional and
post-transcriptional level. ncRNAs can be divided into structural and functional regulatory ncRNAs
and, at the same time, functional ncRNAs can be subdivided into two main groups according their
length; the short ncRNAs (<30 nts) and the long ncRNAs (>200 nts). The amount of ncRNAs
codified in the human genome is unknown; however, recent bioinformatic studies have described
the sequence of thousands of them [5]. ncRNAs genes include those that are extremely high
expressed and showing essential cell functions such as Table 1 describes. A huge contribution to the
identification of untranslated sequences has been the ENcyClopedia of DNA Elements (ENCODE
http://www.genome.gov/encode/), released in September 2003. The conclusions from this pilot
project were published in June 2007 [6]. ENCODE Project was focused on defining RNA transcripts,
transcriptional regulator binding sites, and chromatin states in many cell types by different approaches:
(a) genomics, to find functional elements where mutations and knock-down models demonstrate the
phenotype associated to the genomic sequence; (b) evolutive conservation, as indicator of functional
sequences and (c) biochemical approach in models, to characterize ncRNA activity in specific cell type,
condition, and molecular processes [7]. Bioinformatic studies on gene regulation and RNA metabolism
have described a new variety of functional non-coding sequences, including promoters, enhancers,
silencers, insulators, and ncRNA genes. These non-coding elements are associated with chromatin
structures or transcription enhancers displaying, for example, histone modifications, DNA methylation,
DNase and transcription factor accessibility [8–13]. Some of them could be considered at some point as
‘structural sequences’. YRNAs, for instance, are stem loops essential for DNA replication interacting
with chromatin and initiation proteins (including the origin recognition complex) [14,15]. Small RNAs
are able to modify chromatin structure and to silence transcription by guiding Argonaute-containing
complexes to complementary newly transcribed RNAs scaffolds or to gene promoters [16], mediating
histone and DNA methyltransferases recruitment.
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3. miRNAs
In 1993, a new possibility was included in the genomic and regulatory scheme. Victor Ambros,
Rosalind Lee, and Rhonda Feinbaum, during a study of the lin-4 gene controlling the timing of
Caenorhabditiselegans larval development, described the first miRNA repressing the lin-14 gene [17].
miRNAs are small (21–22 nts) ncRNAs that regulate gene expression and play fundamental regulatory
roles in many biological processes [18–20]. miRNAs can inhibit the translation of hundreds of
mRNAs through sequence specific recognition to the “seed sequence”, and according to the degree of
nucleotide compliment, will raise the inhibition of translation and/or degradation of target molecule
of mRNAs [18–21]. Functional analysis of miRNAs have revealed their significant regulatory influence
on the expression of target genes involved in both physiological and pathological conditions including
gynecological diseases such as endometriosis [22–28].
4. miRNAs Biogenesis
miRNA genes are mainly codified in intergenic or intronic regions of their target genes. In these
cases a miRNA gene is transcribed together with its host gene providing a coupled regulation of
both. Some pri-miRNA may be codified in the intronic regions of protein and non-protein coding
genes or in exons of long non-protein coding RNAs. Consequently, the expression of these miRNAs
could be regulated with their host genes [5]. Other miRNA genes show a common promoter forming
polycistronic units, containing multiple discrete loops from which mature miRNAs are processed.
In the canonical miRNA biogenesis pathways described in Figure 1, pri-miRNAs are trimmed
by the RNAse III Drosha with the help of a double-stranded RNA binding protein: DGCR8.
This protein-complex is known as the Microprocessor and yields ~70 nt stem-loop precursors, termed
pre-miRNA, with two nucleotides overhanging at the 3’ and a 5’-phospate. The pre-miRNA is then
translocated to the cytoplasm by Exportin-5, a Ran-GTP dependent protein [29,30]. From this point on,
further steps are common for miRNAs and exogenous siRNAs.
Once in the cytoplasm, the pre-miRNA is trimmed by Dicer, an RNAse III enzyme, in combination
with TRBP (transactivation Response RNA-Binding Protein) [31]. As a consequence, the loop sequence
of the hairpin is released and Dicer renders a ~22 nt RNA-duplex with short 3’ overhangs. This step
defines the 3’ end of the 5’ strand and the 5’ end of the 3’ strand [18]. Then, Dicer transfers the
RNA-duplex to an Ago (Argonaute) protein, which forms the nucleus of RISC (RNA-Induced Silencing
Complex). At this time, the complex is called the pre-RISC. The mature RISC is achieved once one of
the two strands of the duplex is removed; a process termed “strand selection”.
The main determinant of this process seems to be a thermodynamic factor, mainly determined by
the first four nucleotides of the duplex. Hence, the end with weaker interactions will preferentially
unwind and remain as the “guide strand”, while the so called “passenger strand” will be discarded [30].
The mature RISC complex is able to scan the cytoplasm searching for mRNA able to pair with the
loaded miRNA. The miRNA:mRNA pairing is defined by Watson-Crick interactions between the 3’
UTR (untranslated region) of the mRNA and a short region of nucleotides in positions 2 to 8 of the
miRNA known as the “seed sequence”. It is worthy to mention that beyond this general principle of
miRNA:mRNA interaction, miRNA pairing with the 5’ UTR has also been defined and observed to be
of clinical interest [31] and that additional nucleotides outside the seed sequence can also contribute to
determine the mRNA fate [18].
It is important to highlight that the DNA sequence is not always the template for the mature
miRNA : 6% of human miRNAs suffer RNA editing. In other words, a single pre-miRNA can become
multiple mature miRNAs that differ in their length and sequence, named isomiR. The editing process
can alter the “seed sequence” conferring different affinity for other targets, modifying the mRNA
target selection [5,32]. In this context, the cell-specific expression of different isomiRs implies different
protein expression depending on the cell type conferring the biological significance of these miRNA
variants. This phenomenon increases the spectrum of miRNA action.
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Figure 1. Schematic description of miRNAs biogenesis.  
Silencing of mRNAs can be achieved by means of mRNA cleavage or translational repression. 
Perfect miRNA:mRNA pairing leads to Ago cutting of mRNA approximately at the middle of the 
miRNA length, whereas imperfect pairing mediates mRNA translational repression by different 
mechanisms [18]. 
Apart from the canonical miRNA biogenesis pathway, intronic miRNAs can undergo the 
“mirtron pathway”. In this non-canoncial biogenesis pathway, the spliced intron renders a lariat in 
which the 3’ brachpoint is ligated to the 5’ end of the intron. Following the action of Ldbr (lariat 
debranching enzyme) the lariat is converted in a pre-miRNA that can enter the canonical miRNA 
biogenesis pathway [5,33]. As the vast majority of intronic miRNAs are found on the sense strand it 
seems plausible that their expression may be related to that of the host mRNA [34,35] in terms of 
tissue specificity and relative amount [36]. 
With the avenue of deep-sequencing strategies, the field of miRNAs research has experienced 
an unprecedented growth in terms of genetic origins, biosynthetic pathways, and sequence  
variants [5]. As a result, several ncRNAs have been identified as sources of miRNAs, including 
snoRNA, lncRNA, and tRNA genes with Drosha- and/or Dicer-independent biogenesis [5]. 
5. miRNAs Nomenclature 
The recent advances in high-throughput sequences applied to the miRNA discovery have 
enormously challenged criteria for miRNA annotation. Nomenclature rules are currently defined by 
miRBase 21 [37] and the mature form of the miRNA fit the form hsa-miR-XX-3p/5p, where the prefix 
refers to the species (e.g., hsa- for Homo sapiens). When it is written in capitalized letters, “MIR”, 
refers to the gene that encodes them; and pre-miRNA and pri-miRNA are named as “mir-”. Distinct 
precursor sequences and genomic loci expressing identical mature sequences get names of the form 
hsa-mir-121-1 and hsa-mir-121-2 and adding letters as suffixes denotes mature sequences closely 
related (hsa-miR-121a and hsa-miR-121b) named miR families. Cloning studies sometimes identify 
two mature sequences originated from the same pre-miRNA. The ratio between the two opposite 
mature strands can vary depending on developmental stage, being differentially expressed in 
distinct tissues or cell types, as well as in pathological conditions [5,30]. Previous nomenclature 
versions identified the less expressed strand as asterisk * (hsa-miR-XX *). However, recent studies 
have demonstrated that both strands are functional and the ratio between strands depends on the 
cellular type or status, the annotation criteria was appropriately changed to the current 5p-/3p-end. 
Figure 1. Schematic description of miRNAs biogenesis.
Silencing of mRNAs can be achieved by means of mRNA cleavage or translational repression.
Perfect miRNA:mRNA pairing leads to Ago cutting of mRNA approximately at the middle of the
miRNA length, whereas imperfect pairing mediates mRNA translational repression by different
mechanisms [18].
Apart from the canonical miRNA biogenesis pathway, intronic miRNAs can undergo the “mirtron
pathway”. In this non-canoncial biogenesis pathway, the spliced intron renders a lariat in which the
3’ brachpoint is ligated to the 5’ end of the intron. Following the action of Ldbr (lariat debranching
enzyme) the lariat is converted in a pre-miRNA that can enter the canonical miRNA biogenesis
pathway [5,33]. As the vast majority of intronic miRNAs are found on the sense strand it seems
plausible that their expression may be related to that of the host mRNA [34,35] in terms of tissue
specificity and relative amount [36].
With the avenue of deep-sequencing strategies, the field of miRNAs research has experienced an
unprecedented growth in terms of genetic origins, biosynthetic pathways, and sequence variants [5].
As a result, several ncRNAs have been identified as sources of miRNAs, including snoRNA, lncRNA,
and tRNA genes with Drosha- and/or Dicer-independent biogenesis [5].
5. miRNAs Nomenclature
The recent advances in high-throughput sequences applied to the miRNA discovery have
enormously challenged criteria for miRNA annotation. Nomenclature rules are currently defined
by miRBase 21 [37] and the mature form of the miRNA fit the form hsa-miR-XX-3p/5p, where the
prefix refers to the species (e.g., hsa- for Homo sapiens). When it is written in capitalized letters,
“MIR”, refers to the gene that encodes them; and pre-miRNA and pri-miRNA are named as “mir-”.
Distinct precursor sequences and genomic loci expressing identical mature sequences get names of
the form hsa-mir-121-1 and hsa-mir-121-2 and adding letters as suffixes denotes mature sequences
closely related (hsa-miR-121a and hsa-miR-121b) named miR families. Cloning studies sometimes
identify two mature sequences originated from the same pre-miRNA. The ratio between the two
opposite mature strands can vary depending on developmental stage, being differentially expressed
in distinct tissues or cell types, as well as in pathological conditions [5,30]. Previous nomenclature
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versions identified the less expressed strand as asterisk * (hsa-miR-XX *). However, recent studies
have demonstrated that both strands are functional and the ratio between strands depends on the
cellular type or status, the annotation criteria was appropriately changed to the current 5p-/3p-end.
Apart from the aforementioned miRNA nomenclature, miRBase also identifies mature miRNAs with a
MIMAT accession number. From our own experience, we do recommend authors to refer to studied
miRNAs in their manuscripts with the current -3p or -5p suffix and also to include the miRBase
MIMAT reference and oligonucleotide sequence in order to avoid future misunderstanding that further
nomenclature modifications could introduce.
In the light of current discoveries in miRNA origins, biosynthetic pathways, and sequence
variants, Desvignes and co-workers proposed a revised miRNA nomenclature criterion in the aim of
encompassing recent findings in the field. The authors proposed to modify the miRNA nomenclature
not only based on biogenesis but also on their function [5].
6. Studying miRNAs
In a classic study of miRNAs, the first aim is to assess the miRNA expression profile comparing a
pathological group to a control one. The second step in order to corroborate the profiling results is to
validate the expression of some of selected miRNAs in a larger cohort of samples. Finally, it would
be interesting to prepare functional assays in order to validate the regulation of a specific mRNA
translation by the selected miRNA. Summary of technologies applied in miRNA discovering are listed
in Figure 2.
The most employed techniques in order to assess miRNA expression profiles are next generation
sequencing and microarrays.
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6.1. RNA Sequencing
Next Generation Sequencing (NGS) was initially developed for sequencing genes faster, cheaper
and deeper. The ability to read millions of short fragments of DNA was soon moved into a new
methodology, RNAseq, which includes RNA sequencing and quantification. Total RNA from samples
is digested and retrotrasncribed through ligation of universal primers. cDNA products are then
ligated to primer adaptors for NGS and amplified and isolated in single sequencing reactions on a
surface containing millions of ”nanopore” sequencing reactors. Second generation sequencers are
able to detect millions of isolated sequencing reactions and to generate data related to nucleotide
sequences and the number of reads of each sequence. The bioinformatic software associated with the
NGS sequencer is able to align each short RNA fragment with their corresponding genomic region,
building a complete transcript read. Analogous to qPCR, the number of reads obtained in RNAseq
protocols is correlated to the original amount of cell RNA together with sequence variant detected
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in the alignment. As limitations, the sensibility of NGS is linked to coverage and throughput, so the
presence of over-expressed miRNAs can reduce the ability for detecting miRNAs very low expressed.
6.2. miRNA Microarrays
Microarrays have been a revolution in genomic and proteomics fields because of their ability
to simultaneously detect thousands of molecules. Thereafter, expression assessment moved from
particular genes to whole genomic profiles in which miRNA profiles helped to decode the real
complexity of pathological models [38]. Microarray technology is based on the link of millions of
genomic fragments on a glass support that are used for sample hybridization (Affymetrix, Agilent,
Illumina, NanoString). Samples are fluorescently labeled prior to hybridization. Thus, relative signal
on each probe reflects the original amount of miRNA in the studied sample. Hundreds of new ncRNAs
are described on an annual basis. For this reason, updating and re-designing of non-coding RNA
microarray platforms is mandatory. miRNA expression profiles obtained from microarray platforms
should be validated by qPCR in a larger number of samples.
Both techniques have demonstrated their ability in measuring a large number of miRNAs,
generating a wide amount of results in the discovery phase. However, nowadays the economic
cost is still too expensive to employ them in the validation step. Therefore, quantitative PCR is
confirmed to be the most accurate technique to validate results from RNAseq or microarrays
6.3. Quantitative PCR or Real-Time PCR
Quantitative PCR (qPCR) or Real-Time PCR (RT-PCR) is a fast, easy, and affordable technique
for quantification of miRNAs. Different names depend on applications or thermocycler platforms
employed. PCR allows working with very few amount of starting RNA. The first step consists in
the synthesis of complementary DNA to miRNA through an adapter following a retrotranscription
protocol (RT-PCR). The exponential amplification process in RT-PCR is an extremely sensitive and
accurate method for detecting molecules at very low level, thus becoming the gold standard method
for quantification of miRNAs in biofluids such as plasma or serum. Few limitations can be attributed
to this technique, for example, the limited number of molecules detected depending on plate design
(96- or 384-well plate). Pre-amplification and amplification increase sensitivity quantification can be
biased in low expressed sequences due to diverse protocol steps. On the other hand, normalization
can be difficult because, commonly, “housekeeping” molecules that are used as normalizers can be not
stably expressed in some models or pathologies. In any case, so far, qPCR is the reference method for
expression validation of other techniques in miRNA research [39]. Nowadays, some high-throughput
PCR designed plates are called arrays (Applied, Qiagen, Exiqon). These plates include a customized
selection of probes ready-to-use in order to quantify a high number of miRNAs from a single sample
reducing technical variations.
6.4. In Situ Hybridization (ISH) and Live Cell miRNA Detection
Some companies already specialized in miRNA detection have also developed fluorescent or
antibody-conjugated colored-coupled probes for in situ miRNA detection (Exiqon, Merk-Millipore).
These methodologies allow localizing miRNA molecules in cells or tissues, helping to better
characterization of its biogenesis, pathways, and activity. Fluorescent-labeled probes show miRNA
localization in fixed or live cells and allow, in some assays, to perform flow sorting of cells expressing
concrete regulators [40]. During ISH, a locked nucleic acid (LNA) probe hybridizes to the target
sequence at elevated temperature, and then the excess probe is washed away. LNA probes are highly
sensitive and have been assayed for therapeutically miRNA antisense therapies [41].
7. miRNAs as Biomarkers
“Biomarker” definition has been revised by the Biomarker Definitions Working Group in 2001 [42]
as “a characteristic that is objectively measured and evaluated as an indication of normal biologic
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processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. In the
“omics” era biomarkers can include clinical scoring systems, proteins, gene expression measurements
of mRNA, miRNA, DNA, genetic variants of DNA, or metabolites [43].
With the aim to better understand the pathophysiology of different diseases, several authors have
reported miRNA expression profiles characteristic of some pathologies (cardiovascular diseases, cancer,
diabetes, sepsis, gynecological diseases) [25,26,28,44,45]. The first approach to define a pathological
miRNA expression profile is to assess the miRNA expression pattern in the pathological tissue in order
to clarify the molecular mechanisms underlying the disease. In this context, miRNAs have reportedly
been found in different body fluids, from urine, serum, and plasma to cerebrospinal fluid [46,47].
The presence of miRNAs in different biofluids could be explained by different
mechanisms [39,43,48,49]: (a) passive release of miRNAs as consequence of tissue injury, chronic
inflammation, cell apoptosis or necrosis, or from cells with a short half-life, such as platelets;
(b) active secretion via cell-derived microvesicles including exosomes microparticles and apoptotic
bodies [50–52]; (c) active secretion by cells in miRNA-protein complexes: High Density Lipoprotein
(HDL) and Low Density Lipoprotein (LDL) [53] and Ago2 [54]. Interestingly, Arroyo and co-workers
suggested that Ago2-associated miRNAs could be ready to regulate gene expression in recipient
cells [54]. Mechanisms (b) and (c) could also offer a rationale for the elevated stability of miRNAs in
an RNAse-rich circulation [49]. In light of this evidence, some authors proposed an hormone-like
mechanism of action for these miRNAs [48,49] and a role into cell-to-cell communication [55–58].
Circulating miRNAs, such as the miRNAs released by cancer cells, can bind to Toll-like
receptors (TLRs) of immune cells, such as TLR7 in mice or TLR8 in human, to activate NFκB [59,60].
This mechanism could partially explain inflammation related to cancer.
Importantly, Mitchell and co-workers showed the potential of blood miRNAs as biomarkers for
prostate cancer [61], paving the way for further characterizations in other pathologies. In addition, the
authors demonstrated that miRNAs were protected from endogenous RNAse activity [61].
8. miRNAs Role in Endometriosis
Different groups, including ours, have studied the potential role of miRNAs in the endometriosis
development over years. miRNAs raise as potent regulators of gene expression in the most important
systems involved in the pathogenesis of endometriosis. As Figure 3 details, cell survival, matrix
remodeling, proliferation, and angiogenesis are essential systems in the pathophysiology of this
disease and all of them are potentially regulated by miRNAs [21,22,25,28,62].
9. Endometriosis
Endometriosis is a benign estrogen-dependent inflammatory disorder characterized by the
presence of endometrial-like tissue outside the uterus. Endometriosis-lesions can be found on the
peritoneum (peritoneal lesions), on the ovary either as superficial implants or as endometriotic cysts,
and as deeply infiltrative lesions that might extend to the bowel, bladder, and ureter. Pelvic adhesions
are often associated with the aforementioned lesions [63]. These lesions are responsible for the
main symptoms of endometriosis, pelvic pain and infertility [64]. Whereas innervation at the site
of endometriotic lesions is involved in pelvic pain [65], inflammation has been also associated with
infertility, what could be explained by a diminished oocyte quality because if their development in an
unfavorable environment [66] and also a compromised endometrial receptivity [67].
Endometriosis has been classified as a tumor-like condition by the World Health Organization
Histologic Classification of Ovarian Tumors [68]. Indeed, endometriosis shares common features with
cancer, as increased local estrogen production, reduced apoptosis, pro-survival, inflammation, tissue
invasion, induction of angiogenesis, and dysfunction of immune cells [69]. Since Sampson reported the
first case of suspected malignant transformation of ovarian endometriosis [70], several studies have
focused on the relationship between endometriosis and gynecological cancers, especially endometrioid
and clear cell ovarian carcinoma [71–74]. However, in a recent review, Guo pointed that existing data
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is not enough to establish a doubtless causality and highlighted the need for further molecular studies
in order to establish an unequivocal phylogenetic relationship between both conditions [69].
Despite its high prevalence and incapacitating symptoms, the exact etiopathogenic mechanism of
endometriosis remains unsolved. Burney and Giudice reviewed the theories purposed in recent
years with the aim of providing a plausible etiopathogenic mechanism for endometriosis [75].
However, nowadays, the most accepted theory is by far Sampson’s retrograde menstruation proposal,
which points that during menstruation, endometrial fragments could migrate through fallopian tubes
and reach the peritoneum, being capable to attach, survive, and implant at different locations [70].
It has been demonstrated that all these mechanisms responsible for endometriosis development can be
regulated by miRNAs as Figure 3 shows.
10. Studying New Biomarkers of Endometriosis
The current gold standard for the diagnosis of endometriosis is laparoscopic examination
with histological confirmation of glands and/or stroma in the excised lesions [76]. The need for
surgical procedure for diagnosis together with the fear of a cancer diagnosis and the assumption of
dysmenorrhea as a normal event could explain the aforementioned delay in time to diagnosis [77].
Taking into account that endometriosis has been reported to be progressive in up to 50% of
women [78] and more advanced in women with delayed diagnosis [79] efforts are conducted to
achieve a noninvasive diagnosis. In this context, several approaches have been undertaken, such as
symptom-based tests [80], or blood tests [81–83], but so far neither a non-invasive nor a minimally
invasive test has been achieved, remaining as a priority in endometriosis research [84]. Therefore, an
ideal test for diagnosis of endometriosis should diagnose patients at initial stages with high sensitivity
and specificity.
Due to the anatomical location of this condition, several closely related biofluids have been
proposed as a source for noninvasive biomarkers of endometriosis, for instance: urine, plasma/serum,
and menstrual blood. In addition, the finding that retrograde menstruation is present in 90% of
women but not all of them suffer from endometriosis [67,85] suggests that molecular differences
between eutopic endometrium from women with and without endometriosis may exist that lead
to the development of the condition in certain women but not in others [67]. As a consequence,
if these molecular differences were found to be pathognomonic of the condition they could also
provide an opportunity to be considered as biomarkers in biopsied tissues obtained via a minimally
invasive procedure.
In the field of miRNAs, differences in miRNA expression between endometriotic lesions
and eutopic endometrium from women with endometriosis have been reported [27,86] but few
studies have focused in differences between eutopic endometrium from women with and without
endometriosis [21,27,87].
Burney et al. published one of the first studies addressing the miRNA expression profile in the
endometrium of women with and without endometriosis [21]. In this study, miRNA arrays were
performed and after qRT-PCR validation, the authors reported a downregulation of four miRNAs
(miR-34c-5p, miR-9, miR-9 *, miR-34b *) in the eutopic endometrium from women with endometriosis
compared to control endometrium. According to the miRNA regulatory mechanisms, downregulated
levels of a miRNA entails the upregulation of its target mRNA translation. Laudanski et al. conducted a
study enrolling 25 endometriosis-free women and 21 patients with ovarian endometriosis in which the
expression of 667 human miRNAs was examined by means of PCR arrays. Validation of the results led
to the corroboration that miR-483-5p, a regulator of IGF2, and miR-629-3p, involved in inflammation,
were downregulated in the eutopic endometrium of patients in comparison to controls. The authors
pointed to the idea that dysregulation of these genes could contribute to the overgrowth of endometrial
tissue outside the uterus [87].
Human endometrium is a unique tissue that undergoes complex molecular, cellular, and
functional changes on a cyclic basis under ovarian hormone regulation [88–90]. These changes are
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essential for uterine receptivity and can be grouped in three distinct phases: proliferative, secretory,
and menstrual [90]. Some authors have described that miRNA expression vary across the menstrual
cycle [24]. Particularly, miRNAs targeting several cell cycle regulators were over-expressed in the
secretory phase [23].
Angiogenesis also plays an important role in the pathogenesis of endometriosis, due that
ectopic lesions require neovascularization to proliferate, invade the extracellular matrix and
proliferate [27,28,91]. Both Vascular Endothelial Growth Factor A (VEGF-A) and Thrombospondin-1
(TSP-1) represent the most potent pro- and anti-angiogenic factors, respectively, and have been
involved in the pathology of endometriosis [92]. Our research group has reportedly observed an
increase in the expression of angiogenic and proteolytic factors in endometrial tissues from patients
with endometriosis [93,94] and we have suggested that this increase might contribute to the invasive
potential of endometrial cells.
The miRNA regulation of angiogenesis has been long reported in several pathologies, including
endometriosis [27,28,86,87,95,96]. Two different groups have reported that the angiogenesis regulators,
miR-17-5p and miR-20a, are downregulated in the ovarian endometrioma compared to eutopic
endometrium [24,87]. The miR-17-92 cluster, also known as oncomir-1, encodes six mature miRNAs
(miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92a) [97]. Recently, our group has reported
that the miR-17-92 cluster increases tumour neovascularization by decreasing TSP-1 expression [98].
Therefore, and due to the miRNA mechanism action, a decrease in miR-17-5p levels involve
post-transcriptional upregulation of TSP-1 levels. This mechanism may reduce the angiogenic
activity in the ovarian endometrioma; therefore, it could explain the low ability in the extracellular
matrix invasion of this tissue observed in these ectopic lesions where frequently the ovarian tissue
remains preserved.
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11. Circulating miRNAs as Biomarkers of Endometriosis
The study of circulating miRNAs as biomarkers of endometriosis is an emerging field of research,
and to date only few studies have been published both in serum [82] and plasma [81,83].
Wang et al. [99] first performed a circulating miRNA array profiling in two pools of sera from
10 patients with endometriosis and 10 control women. After validation of results from array by
qRT-PCR in sera from 60 patients and 25 control women, the authors found that miR-199a and miR-122
levels were upregulated and miR-145 *, miR-141 *, miR-542-3p, and miR-9 * downregulated in samples
from patients in comparison to control women and could therefore serve as biomarkers of the disease.
Shortly after, another study in plasma was conducted by Jia et al. [81]. 23 women with
histologically proven endometriosis and 23 endometriosis-free controls were enrolled in the study and
a miRNA microarray profiling was performed. Three out of the six miRNAs selected for validation by
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qRT-PCR (miR-17-5p, miR-20a, and miR-22) were proven to be significantly downregulated in patients
and useful to discriminate women with endometriosis from patients.
In 2015, two studies have been published, extending the evidence of miRNAs as putative
biomarkers of endometriosis in non-invasive biofluids. In the first case, levels of previously
endometriosis-associated miRNAs, miR-135a,b and let-7a-f, were quantified in sera of 24 endometriosis
patients and 24 control women. By means of a logistic regression approach, researchers found that
combining levels of let-7b, let-7d, and let-7f in the proliferative phase obtained the highest area under
the curve value in order to discriminate patients with endometriosis from control women. [82]. Of
note, several miRNAs were found to be differently expressed depending on the phase of the menstrual
cycle in patients but not in controls, in agreement with previous reports [100]. Finally, Rekker et al [83]
performed the last published study regarding circulating miRNAs as biomarkers of endometriosis.
Based on previous literature, authors selected three miRNAs from the miR-200 family (miR-200a-3p,
miR-200b-3p, and miR-141-3p) whose expression was assessed in plasma samples from 61 patients
and 65 control women. The expression of all three miRNAs was downregulated in patients and
miR-200a-3p and miR-141-3p showed the highest potential as noninvasive biomarkers for this benign
condition. Remarkably, authors also analyzed variations of the levels of the three miRNAs of interest
with time of sampling (morning/evening) finding lower levels in evening samples, perhaps due to
circadian fluctuations in their expression. This is an interesting approach and points to the time of
sampling as an important factor to be taken into account when performing circulating miRNAs studies.
12. Conclusions
Among the epigenetic players, miRNAs have emerged as pivotal post-transcriptional regulators.
To do this, these small non-coding RNAs bind to their target mRNAs and inhibit the translation
process. The involvement of miRNAs in different pathological conditions has been well established
and the miRNA expression profiles have been performed in biopsies from different diseases, including
gynecological pathologies as endometriosis. Despite being a benign gynecological pathology,
endometriosis deeply impairs the quality of life of affected women in terms of pain and infertility.
Nowadays, the gold standard to diagnose endometriosis is laparoscopy. For this reason, several
groups including ours are focused on characterizing a non-invasive or semi-invasive biomarker for
the diagnosis of endometriosis at initial stages that overcomes the need for the current laparoscopy.
Recently, circulating miRNAs have emerged as attractive molecules to be considered as biomarkers [45],
although deeper studies are required in order to characterize and validate a miRNA-based diagnostic
tool. It is important to highlight the important differences in experimental design and preanalytical
protocols among different studies evaluating the same pathology; making it difficult to compare
results [40]. For all these reasons, the World Endometriosis Research Foundation (WERF) has
published recommendations in order to standardize the data and sample collection, processing and
storage [101–104] and reduce the heterogeneity and improve the reproducibility between studies as
summarize the Figure 4. It is essential to unify every step in endometriosis research. The first one is
data collection; for this purpose the WERF have elaborated a guide for surgical data collection as well
as video/photo of symptom documentation [101,102]. Regarding the study of biofluids, the WERF has
defined the protocol in order to standardize the biospecimen collection, processing, and storage [103].
Finally, the collection and storage of tissue samples have also been standardized according to the
consensus document [104]. All these documents [101–104] allow for unifying the studies performed
around the world about endometriosis. The aforementioned guides could be also useful for the study
and validation in other diseases; these steps avoid the publication of dissimilar studies performed in
the “same” disease but employing different protocols. This could be a simple way to obtain robust
conclusions and be able to standardize new biomarkers. However, the study of miRNAs as biomarkers
implies additional considerations. As it has been previously described, miRNAs are very stable
circulating molecules; however heterogeneity among patients seems to be substantial. This feature
is even more evident when results from one study are replicated by other group. Based on our own
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experience, pharmacological treatments, clinical conditions, or even diet can affect severely miRNA
expression profiles in plasma.
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